Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma

Anna-Maria Spektor, Ewgenija Gutjahr, Matthias Lang, Frederik M. Glatting, Thilo Hackert, Thomas Pausch, Christine Tjaden, Mathias Schreckenberger, Uwe Haberkorn, Manuel Röhrich
{"title":"Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma","authors":"Anna-Maria Spektor, Ewgenija Gutjahr, Matthias Lang, Frederik M. Glatting, Thilo Hackert, Thomas Pausch, Christine Tjaden, Mathias Schreckenberger, Uwe Haberkorn, Manuel Röhrich","doi":"10.2967/jnumed.123.266393","DOIUrl":null,"url":null,"abstract":"<p>Pancreatic intraductal papillary mucinous neoplasms (IPMNs) are grossly visible (typically &gt; 5 mm) intraductal epithelial neoplasms of mucin-producing cells, arising in the main pancreatic duct or its branches. According to the current 2-tiered grading scheme, these lesions are categorized as having either low-grade (LG) dysplasia, which has a benign prognosis, or high-grade (HG) dysplasia, which formally represents a carcinoma in situ and thus can transform to pancreatic ductal adenocarcinoma (PDAC). Because both entities require different treatments according to their risk of becoming malignant, a precise pretherapeutic diagnostic differentiation is inevitable for adequate patient management. Recently, our group has demonstrated that <sup>68</sup>Ga-fibroblast activation protein (FAP) inhibitor (FAPI) PET/CT shows great potential for the differentiation of LG IPMNs, HG IPMNs, and PDAC according to marked differences in signal intensity and tracer dynamics. The purpose of this study was to biologically validate FAP as a target for PET imaging by analyzing immunohistochemical FAP expression in LG IPMNs, HG IPMNs, and PDAC and comparing with SUV and time to peak (TTP) measured in our prior study. <b>Methods:</b> To evaluate the correlation of the expression level of FAP and &alpha;-smooth muscle actin (&alpha;SMA) in neoplasm-associated stroma depending on the degree of dysplasia in IPMNs, 98 patients with a diagnosis of LG IPMN, HG IPMN, PDAC with associated HG IPMN, or PDAC who underwent pancreatic surgery at the University Hospital Heidelberg between 2017 and 2023 were identified using the database of the Institute of Pathology, University Hospital Heidelberg. In a reevaluation of hematoxylin- and eosin-stained tissue sections of formalin-fixed and paraffin-embedded resection material from the archive, which was originally generated for histopathologic routine diagnostics, a regrading of IPMNs was performed by a pathologist according to the current 2-tiered grading scheme, consequently eliminating the former diagnosis of \"IPMN with intermediate-grade dysplasia.\" For each case, semithin tissue sections of 3 paraffin blocks containing neoplasm were immunohistologically stained with antibodies directed against FAP and &alpha;SMA. In a masked approach, a semiquantitative analysis of the immunohistochemically stained slides was finally performed by a pathologist by adapting the immunoreactive score (IRS) and human epidermal growth factor receptor 2 (Her2)/neu score to determine the intensity and percentage of FAP- and &alpha;SMA-positive cells. Afterward, the IRS of 14 patients who underwent <sup>68</sup>Ga-FAPI-74 PET/CT in our previous study was compared with their SUV<SUB>max</SUB>, SUV<SUB>mean</SUB>, and TTP for result validation. <b>Results:</b> From 98 patients, 294 specimens (3 replicates per patient) were immunohistochemically stained for FAP and &alpha;SMA. Twenty-three patients had LG IPMNs, 11 had HG IPMNs, 10 had HG IPMNs plus PDAC, and 54 had PDAC. The tumor stroma was in all cases variably positive for FAP. The staining intensity, percentage of FAP-positive stroma, IRS, and Her2/neu score increased with higher malignancy. &alpha;SMA expression could be shown in normal pancreatic stroma as well as within peri- and intraneoplastic desmoplastic reaction. No homogeneous increase in intensity, percentage, IRS, and Her2/neu score with higher malignancy was observed for &alpha;SMA. The comparison of the mean IRS of FAP with the mean SUV<SUB>max</SUB>, SUV<SUB>mean</SUB>, and TTP of <sup>68</sup>Ga-GAPI-74 PET/CT showed a matching value increasing with higher malignancy in <sup>68</sup>Ga-FAPI-74 PET imaging and immunohistochemical FAP expression. <b>Conclusion:</b> The immunohistochemical staining of IPMNs and PDAC validates FAP as a biology-based stromal target for in&nbsp;vivo imaging. Increasing expression of FAP in lesions with a higher degree of malignancy matches the expectation of a stronger FAP expression in PDAC and HG IPMNs than in LG IPMNs and corroborates our previous findings of higher SUVs and a longer TTP in PDAC and HG IPMNs than in LG IPMNs.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.123.266393","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pancreatic intraductal papillary mucinous neoplasms (IPMNs) are grossly visible (typically > 5 mm) intraductal epithelial neoplasms of mucin-producing cells, arising in the main pancreatic duct or its branches. According to the current 2-tiered grading scheme, these lesions are categorized as having either low-grade (LG) dysplasia, which has a benign prognosis, or high-grade (HG) dysplasia, which formally represents a carcinoma in situ and thus can transform to pancreatic ductal adenocarcinoma (PDAC). Because both entities require different treatments according to their risk of becoming malignant, a precise pretherapeutic diagnostic differentiation is inevitable for adequate patient management. Recently, our group has demonstrated that 68Ga-fibroblast activation protein (FAP) inhibitor (FAPI) PET/CT shows great potential for the differentiation of LG IPMNs, HG IPMNs, and PDAC according to marked differences in signal intensity and tracer dynamics. The purpose of this study was to biologically validate FAP as a target for PET imaging by analyzing immunohistochemical FAP expression in LG IPMNs, HG IPMNs, and PDAC and comparing with SUV and time to peak (TTP) measured in our prior study. Methods: To evaluate the correlation of the expression level of FAP and α-smooth muscle actin (αSMA) in neoplasm-associated stroma depending on the degree of dysplasia in IPMNs, 98 patients with a diagnosis of LG IPMN, HG IPMN, PDAC with associated HG IPMN, or PDAC who underwent pancreatic surgery at the University Hospital Heidelberg between 2017 and 2023 were identified using the database of the Institute of Pathology, University Hospital Heidelberg. In a reevaluation of hematoxylin- and eosin-stained tissue sections of formalin-fixed and paraffin-embedded resection material from the archive, which was originally generated for histopathologic routine diagnostics, a regrading of IPMNs was performed by a pathologist according to the current 2-tiered grading scheme, consequently eliminating the former diagnosis of "IPMN with intermediate-grade dysplasia." For each case, semithin tissue sections of 3 paraffin blocks containing neoplasm were immunohistologically stained with antibodies directed against FAP and αSMA. In a masked approach, a semiquantitative analysis of the immunohistochemically stained slides was finally performed by a pathologist by adapting the immunoreactive score (IRS) and human epidermal growth factor receptor 2 (Her2)/neu score to determine the intensity and percentage of FAP- and αSMA-positive cells. Afterward, the IRS of 14 patients who underwent 68Ga-FAPI-74 PET/CT in our previous study was compared with their SUVmax, SUVmean, and TTP for result validation. Results: From 98 patients, 294 specimens (3 replicates per patient) were immunohistochemically stained for FAP and αSMA. Twenty-three patients had LG IPMNs, 11 had HG IPMNs, 10 had HG IPMNs plus PDAC, and 54 had PDAC. The tumor stroma was in all cases variably positive for FAP. The staining intensity, percentage of FAP-positive stroma, IRS, and Her2/neu score increased with higher malignancy. αSMA expression could be shown in normal pancreatic stroma as well as within peri- and intraneoplastic desmoplastic reaction. No homogeneous increase in intensity, percentage, IRS, and Her2/neu score with higher malignancy was observed for αSMA. The comparison of the mean IRS of FAP with the mean SUVmax, SUVmean, and TTP of 68Ga-GAPI-74 PET/CT showed a matching value increasing with higher malignancy in 68Ga-FAPI-74 PET imaging and immunohistochemical FAP expression. Conclusion: The immunohistochemical staining of IPMNs and PDAC validates FAP as a biology-based stromal target for in vivo imaging. Increasing expression of FAP in lesions with a higher degree of malignancy matches the expectation of a stronger FAP expression in PDAC and HG IPMNs than in LG IPMNs and corroborates our previous findings of higher SUVs and a longer TTP in PDAC and HG IPMNs than in LG IPMNs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
免疫组化 FAP 表达反映低级别和高级别导管内乳头状黏液瘤和胰腺导管腺癌的 68Ga-FAPI PET 成像特性
胰腺导管内乳头状粘液瘤(IPMNs)是指在主胰管或其分支中出现的大体可见(通常为 5 毫米)的导管内上皮肿瘤,由产生粘液的细胞组成。根据目前的两级分级方案,这些病变可分为低级别(LG)发育不良和高级别(HG)发育不良,前者预后良好,后者则正式代表原位癌,因此可转化为胰腺导管腺癌(PDAC)。由于这两种实体都需要根据其恶变风险采取不同的治疗方法,因此要对患者进行适当的管理,就必须在治疗前进行精确的诊断鉴别。最近,我们的研究小组证实,68Ga-成纤维细胞活化蛋白(FAP)抑制剂(FAPI)PET/CT 在根据信号强度和示踪剂动态的明显差异区分 LG IPMNs、HG IPMNs 和 PDAC 方面显示出巨大的潜力。本研究的目的是通过分析免疫组化法 FAP 在 LG IPMNs、HG IPMNs 和 PDAC 中的表达,并与我们之前研究中测得的 SUV 和达峰时间 (TTP) 进行比较,从生物学角度验证 FAP 作为 PET 成像的靶点。方法为了评估FAP和平滑肌肌动蛋白(α-smooth muscle actin,αSMA)在肿瘤相关基质中的表达水平与IPMNs发育不良程度的相关性,我们利用海德堡大学医院病理学研究所的数据库,对2017年至2023年间在海德堡大学医院接受胰腺手术的98例诊断为LG IPMN、HG IPMN、伴有HG IPMN的PDAC或PDAC的患者进行了鉴定。在重新评估档案中福尔马林固定和石蜡包埋切除材料的苏木精和伊红染色组织切片时,病理学家根据现行的两级分级方案对IPMN进行了重新分级,从而取消了之前的 "中级发育不良的IPMN "诊断。用针对 FAP 和αSMA 的抗体对每个病例中含有肿瘤的 3 块石蜡切片进行免疫组化染色。最后,由病理学家对免疫组化染色的切片进行半定量分析,通过免疫反应评分(IRS)和人表皮生长因子受体 2(Her2)/neu 评分来确定 FAP 和 SMA 阳性细胞的强度和百分比。随后,将我们之前研究中接受 68Ga-FAPI-74 PET/CT 的 14 例患者的 IRS 与他们的 SUVmax、SUVmean 和 TTP 进行比较,以验证结果。结果:对98名患者的294份标本(每名患者3份)进行了FAP和αSMA免疫组化染色。23 例患者为 LG IPMN,11 例为 HG IPMN,10 例为 HG IPMN 加 PDAC,54 例为 PDAC。所有病例的肿瘤基质均呈不同程度的 FAP 阳性。染色强度、FAP阳性基质百分比、IRS和Her2/neu评分随着恶性程度的升高而升高。正常胰腺基质以及瘤周和瘤内去瘤细胞反应均可显示αSMA表达。未观察到αSMA的强度、百分比、IRS和Her2/neu评分随着恶性程度的增加而均匀增加。FAP 的平均 IRS 与 68Ga-GAPI-74 PET/CT 的平均 SUVmax、SUVmean 和 TTP 的比较显示,68Ga-FAPI-74 PET 成像和免疫组化 FAP 表达的匹配值随着恶性程度的增加而增加。结论IPMNs和PDAC的免疫组化染色验证了FAP是基于生物学的体内成像基质靶点。在恶性程度较高的病变中,FAP的表达增加,这与PDAC和HG IPMNs中FAP表达强于LG IPMNs的预期相吻合,也证实了我们之前的发现,即PDAC和HG IPMNs的SUV较高,TTP较LG IPMNs长。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Precautions to Consider in the Analysis of Prognostic and Predictive Indices Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study [18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy MIRD Pamphlet No. 31: MIRDcell V4—Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1